Literature DB >> 15046598

Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes.

D A Fruman1.   

Abstract

The PI3K (phosphoinositide 3-kinase) signalling pathway promotes proliferation and transformation in many cell types. This is particularly well illustrated by studies of primary lymphocytes and their leukaemic counterparts. PI3K activation is required for proliferation of T cells and B cells, and certain oncogenes cause leukaemia in part by promoting PI3K signalling. Genetic manipulation of this pathway, together with biochemical studies in primary lymphocytes, has begun to shed light on the molecular mechanisms by which PI3K contributes to the proliferation of normal and transformed lymphocytes. In particular, targeted gene disruption in mice has allowed the identification of specific isoforms of PI3K that are required for distinct cellular responses. Continued investigation of isoform specificity in PI3K signalling, as well as the characterization of critical downstream targets of PI3K signalling, may reveal strategies for the therapeutic control of immune responses and leukaemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046598     DOI: 10.1042/bst0320315

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  13 in total

Review 1.  The survival kinases Akt and Pim as potential pharmacological targets.

Authors:  Ravi Amaravadi; Craig B Thompson
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 2.  Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase.

Authors:  J S Oak; M P Matheu; I Parker; M D Cahalan; D A Fruman
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

Review 3.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

4.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

5.  Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.

Authors:  Kazuhiko Haruta; Shigeyuki Mori; Naoto Tamura; Asako Sasaki; Masakazu Nagamine; Shin-ichi Yaguchi; Fumitaka Kamachi; Jumpei Enami; Shigeto Kobayashi; Takao Yamori; Yoshinari Takasaki
Journal:  Inflamm Res       Date:  2012-02-15       Impact factor: 4.575

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 7.  Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.

Authors:  Sarah E M Herman; Amy J Johnson
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

Review 8.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Authors:  Yoshihiro Ito; Jonathan R Hart; Peter K Vogt
Journal:  Expert Opin Ther Targets       Date:  2018-09-24       Impact factor: 6.902

Review 10.  The Interplay between NLRs and Autophagy in Immunity and Inflammation.

Authors:  Leticia A M Carneiro; Leonardo H Travassos
Journal:  Front Immunol       Date:  2013-11-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.